Download PDF
Aktuelle Dermatologie 2024; 50(12): 564-571
DOI: 10.1055/a-2317-9979
Übersicht

Medikamentöse Therapien des Ulcus cruris

Drug therapies for Ulcus cruris
Moritz Ronicke
1   Hautklinik, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Deutschland
,
Cornelia Erfurt-Berge
1   Hautklinik, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Deutschland
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Chronische Wunden belasten viele Patienten in Deutschland sowie weltweit. Medikamentöse Therapien spielen aktuell bei den häufigeren Ursachen wie dem Ulcus cruris venosum oder dem Ulcus cruris arteriosum noch eine untergeordnete Rolle, obwohl für einzelne Therapien gute Daten vorliegen. Für seltenere Krankheitsbilder wie Kalziphylaxie, Necrobiosis lipoidica und Pyoderma gangraenosum mangelt es oft an belastbaren Studien. Medikamentöse Behandlungen sind hier jedoch für die Abheilung essenziell. Insgesamt mangelt es bei allen genannten Erkrankungen an zugelassenen Therapien. In diesem Artikel werden mögliche medikamentöse Therapieoptionen bei allen genannten Erkrankungen diskutiert.

Abstract

Chronic wounds are a burden for many patients in Germany and around the world. Drug therapies still play a subordinate role for the more common causes such as venous leg ulcers or arterial leg ulcers, although good data is available for individual therapies. For rarer entities, such as calciphylaxis, necrobiosis lipoidica and pyoderma gangrenosum, there is often a lack of reliable studies. However, drug treatments are essential for healing in those cases. Overall, there is a lack of approved therapies for all the diseases mentioned. This article discusses possible drug therapy options for all the diseases mentioned.



Publication History

Article published online:
21 June 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Dissemond J, Bültemann A, Gerber V. et al. Standards für die Diagnostik und Therapie chronischer Wunden Stand 2020. Initiative Chronische Wunden. 2020 1–19
    PubMedSearch in Google Scholar
  • 2 Dissemond J, Erfurt-Berge C, Goerge T. et al. Systemic therapies for leg ulcers. J Dtsch Dermatol Ges 2018; 16: 873-892
    CrossrefPubMedSearch in Google Scholar
  • 3 González-Consuegra RV, Verdú J. Quality of life in people with venous leg ulcers: An integrative review. J Adv Nurs 2011; 67: 926-944
    CrossrefPubMedSearch in Google Scholar
  • 4 Margolis DJ, Bilker W, Santanna J. et al. Venous leg ulcer: Incidence and prevalence in the elderly. J Am Acad Dermatol 2002; 46: 381-386
    CrossrefPubMedSearch in Google Scholar
  • 5 Fernandes Abbade LP, Lastória S. Venous ulcer: Epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol 2005; 44: 449-456
    CrossrefPubMedSearch in Google Scholar
  • 6 Jull A, Wadham A, Bullen C. et al. Low dose aspirin as adjuvant treatment for venous leg ulceration: pragmatic, randomised, double blind, placebo controlled trial (Aspirin4VLU). BMJ 2017; 359: j5157
    CrossrefPubMedSearch in Google Scholar
  • 7 Helen T, Liz C, Laura C. et al. Aspirin versus placebo for the treatment of venous leg ulcers – A phase II, pilot, randomised trial (AVURT). Trials 2019; 20: 459
    CrossrefPubMedSearch in Google Scholar
  • 8 Weller CD, Martin C, Bouguettaya A. et al. Once daily 300 mg aspirin with compression versus compression alone in patients with chronic venous leg ulcers (ASPiVLU): A randomised, double-blinded, multicentre, placebo-controlled, clinical trial. J Tissue Viability 2021; 30: 509-516
    CrossrefPubMedSearch in Google Scholar
  • 9 Mulloy B, Hogwood J, Gray E. et al. Pharmacology of Heparin and Related Drugs. Pharmacol Rev 2015; 68: 76-141
    CrossrefPubMedSearch in Google Scholar
  • 10 Serra R, Buffone G, Molinari V. et al. Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly. Int Wound J 2015; 12: 150-153
    CrossrefPubMedSearch in Google Scholar
  • 11 Jull AB, Arroll B, Parag V. et al. Pentoxifylline for treating venous leg ulcers. Cochrane Database of Systematic Reviews 2012; 12: CD001733
    CrossrefPubMedSearch in Google Scholar
  • 12 Shi C, Dumville JC, Cullum N. et al. Compression bandages or stockings versus no compression for treating venous leg ulcers. Cochrane Database Syst Rev 2021; 2021: CD013397
    CrossrefPubMedSearch in Google Scholar
  • 13 Evangelista MTP, Casintahan MFA, Villafuerte LL. Simvastatin as a novel therapeutic agent for venous ulcers: A randomized, double-blind, placebo-controlled trial. Brit J Dermatol 2014; 170: 1151-1157
    CrossrefPubMedSearch in Google Scholar
  • 14 Jull A, Lu H, Jiang Y. Statins and venous leg ulcer healing Secondary analysis of data from a cohort of three randomised controlled trials. Wound Repair and Regeneration 2021; 30: 186-189
    CrossrefPubMedSearch in Google Scholar
  • 15 Scallon C, Bell-Syer SEM, Aziz Z. Flavonoids for treating venous leg ulcers. Cochrane Database Syst Rev 2013; 2013: CD006477
    CrossrefPubMedSearch in Google Scholar
  • 16 O’Donnell TF, Passman MA, Marston WA. et al. Management of venous leg ulcers: Clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum. J Vasc Surg 2014; 60: 3S-59S
    CrossrefPubMedSearch in Google Scholar
  • 17 John J, Tate S, Price A. Non-surgical treatment for arterial leg ulcers: a narrative review. J Wound Care [Internet] 2022; 31: 969-978
    CrossrefPubMedSearch in Google Scholar
  • 18 Lawall H, Huppert P, Rümenapf G. et al. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. AWMF [Internet]. 2015
    PubMedSearch in Google Scholar
  • 19 Norgren L, Hiatt WR, Dormandy JA. et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45: S5-S67
    CrossrefPubMedSearch in Google Scholar
  • 20 Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa 2004; 33: 137-144
    CrossrefPubMedSearch in Google Scholar
  • 21 Robertson I, Kessel DO, Berridge DC. Fibrinolytic agents for peripheral arterial occlusion. Vol. 2013, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2013
    Search in Google Scholar
  • 22 Schiffmann ML, Dissemond J, Erfurt-Berge C. et al. S1-Leitlinie Diagnostik und Therapie der Livedovaskulopathie. J Dtsch Dermatol Ges 2021; 19: 1667-1678
    CrossrefPubMedSearch in Google Scholar
  • 23 Weishaupt C, Strölin A, Kahle B. et al. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): A multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol 2016; 3: e72-e79
    CrossrefPubMedSearch in Google Scholar
  • 24 Nigwekar SU, Bloch DB, Nazarian RM. et al. Vitamin K-Dependent carboxylation of matrix gla protein influences the risk of calciphylaxis. Journal of the American Society of Nephrology 2017; 28: 1717-1722
    CrossrefPubMedSearch in Google Scholar
  • 25 Zitt E, König M, Vychytil A. et al. Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrology Dialysis Transplantation 2013; 28: 1232-1240
    CrossrefPubMedSearch in Google Scholar
  • 26 Nigwekar SU, Brunelli SM, Meade D. et al. Sodium Thiosulfate therapy for Calcific Uremic Arteriolopathy. Clinical Journal of the American Society of Nephrology 2013; 8: 1162-1170
    CrossrefPubMedSearch in Google Scholar
  • 27 Truong DH, Riedhammer MM, Zinszer K. Non-uraemic calciphylaxis successfully treated with pamidronate infusion. Int Wound J 2019; 16: 250-255
    CrossrefPubMedSearch in Google Scholar
  • 28 Fuchs F, Franke I, Tüting T. et al. Successful treatment of non-uremic calciphylaxis with bisphosphonate. J Dtsch Dermatol Ges 2020; 18: 1498-1500
    CrossrefPubMedSearch in Google Scholar
  • 29 Peng T, Zhuo L, Wang Y. et al. Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients. Nephrology 2018; 23: 669-675
    CrossrefPubMedSearch in Google Scholar
  • 30 Ross EA. Evolution of treatment strategies for calciphylaxis. American Journal of Nephrology 2011; 34: 460-467
    CrossrefPubMedSearch in Google Scholar
  • 31 Torregrosa JV, Sánchez-Escuredo A, Barros X. et al. Clinical management of calcific uremic arteriolopathy before and after therapeutic inclusion of bisphosphonates. Clin Nephrol 2015; 83: 231-234
    PubMedSearch in Google Scholar
  • 32 Floege J, Kubo Y, Floege A. et al. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: The EVOLVE trial. Clinical Journal of the American Society of Nephrology 2015; 10: 800-807
    CrossrefPubMedSearch in Google Scholar
  • 33 Deen J, Schaider H. The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: A comprehensive review. Australasian Journal of Dermatology 2019; 60: e186-e194
    CrossrefPubMedSearch in Google Scholar
  • 34 Russell R, Brookshire MA, Zekonis M. et al. Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca P product and aggressive wound care. Clin Nephrol 2002; 58: 238-243
    CrossrefPubMedSearch in Google Scholar
  • 35 El-Azhary RA, Arthur AK, Davis MDP. et al. Retrospective Analysis of Tissue Plasminogen Activator as an Adjuvant Treatment for Calciphylaxis. JAMA Dermatol [Internet] 2013; 149: 63-67
    CrossrefPubMedSearch in Google Scholar
  • 36 Sewell LD, Weenig RH, Davis MDP. et al. Low-Dose Tissue Plasminogen Activator for Calciphylaxis. Arch Dermatol [Internet] 2004; 140: 1045-1048
    CrossrefPubMedSearch in Google Scholar
  • 37 Erfurt-Berge C, Dissemond J, Schwede K. et al. Updated results of 100 patients on clinical features and therapeutic options in necrobiosis lipoidica in a retrospective multicentre study. European Journal of Dermatology 2015; 25: 595-601
    CrossrefPubMedSearch in Google Scholar
  • 38 Peckruhn M, Tittelbach J, Elsner P. Update: Therapie der Necrobiosis lipoidica. J Dtsch Dermatol Ges 2017; 15: 151-157
    CrossrefPubMedSearch in Google Scholar
  • 39 Erfurt-Berge C, Heusinger V, Reinboldt-Jockenhöfer F. et al. Comorbidity and Therapeutic Approaches in Patients with Necrobiosis Lipoidica. Dermatology 2022; 238: 148-155
    CrossrefPubMedSearch in Google Scholar
  • 40 Basoulis D, Fragiadaki K, Tentolouris N. et al. Anti-TNFα treatment for recalcitrant ulcerative necrobiosis lipoidica diabeticorum: A case report and review of the literature. Metabolism 2016; 65: 569-573
    CrossrefPubMedSearch in Google Scholar
  • 41 Chapman S, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: Part II. A comprehensive review. Journal of the American Academy of Dermatology 2022; 86: 414-422
    CrossrefPubMedSearch in Google Scholar
  • 42 Erfurt-Berge C, Sticherling M. Successful treatment of ulcerative necrobiosis lipoidica with janus kinase inhibitor. Journal of the European Academy of Dermatology and Venereology 2020; 34: e329-e345
    CrossrefPubMedSearch in Google Scholar
  • 43 Arnet L, Erfurt-Berge C. Effect of abrocitinib in a patient with extensive necrobiosis lipoidica. Journal of the European Academy of Dermatology and Venereology 2023; 37: e1208-e1210
    CrossrefPubMedSearch in Google Scholar
  • 44 Jockenhöfer F, Wollina U, Salva KAA. et al. The PARACELSUS score: A novel diagnostic tool for pyoderma gangrenosum. Brit J Dermatol 2019; 180: 615-620
    CrossrefPubMedSearch in Google Scholar
  • 45 Maverakis E, Le ST, Callen J. et al. New validated diagnostic criteria for pyoderma gangrenosum. J Am Acad Dermatol 2019; 80: e87-e88
    CrossrefPubMedSearch in Google Scholar
  • 46 S1-Leitlinie Pyoderma gangraenosum. AWMF. 2020
    PubMedSearch in Google Scholar
  • 47 Ormerod AD, Thomas KS, Craig FE. et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: Results of the STOP GAP randomised controlled trial. BMJ 2015; 350: h2958
    CrossrefPubMedSearch in Google Scholar
  • 48 Nazir A, Zafar A. Management of Idiopathic Pyoderma Gangrenosum With Azathioprine As the Primary Adjunct in an Asian Man: A Case Report. Cureus 2022; 14: e25177
    PubMedSearch in Google Scholar
  • 49 Eaton PA, Callen JP. Mycophenolate Mofetil as Therapy for Pyoderma Gangrenosum. Arch Dermatol [Internet] 2009; 145: 781-785
    CrossrefPubMedSearch in Google Scholar
  • 50 Teitel AD. Treatment of pyoderma gangrenosum with methotrexate. Cutis [Internet] 1996; 57: 326-328
    PubMedSearch in Google Scholar
  • 51 Song H, Lahood N, Mostaghimi A. Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: Systematic review of cases and case series. Brit J Dermatol 2018; 178: 363-368
    CrossrefPubMedSearch in Google Scholar
  • 52 Haag CK, Ortega-Loayza AG, Latour E. et al. Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum. J Dermatolog Treat 2020; 31: 723-726
    CrossrefPubMedSearch in Google Scholar
  • 53 Brooklyn TN, Dunnill MGS, Shetty A. et al. Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial. Gut 2006; 55: 505-509
    CrossrefPubMedSearch in Google Scholar
  • 54 Yamasaki K, Yamanaka K, Zhao Y. et al. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52-week phase 3 open-label study. J Dermatol 2022; 49: 479-487
    CrossrefPubMedSearch in Google Scholar
  • 55 Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment. Am J Clin Dermatol 2017; 18: 555-562
    CrossrefPubMedSearch in Google Scholar
  • 56 Kolios AGA, Maul JT, Meier B. et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Brit J Dermatol 2015; 173: 1216-1223
    CrossrefPubMedSearch in Google Scholar
  • 57 Sun NZ, Ro T, Jolly P. et al. Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa. J Clin Aesthet Dermatol [Internet] 2017; 10: 36
    PubMedSearch in Google Scholar
  • 58 Caproni M, Antiga E, Volpi W. et al. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Brit J Dermatol 2015; 173: 275-278
    CrossrefPubMedSearch in Google Scholar
  • 59 Burgdorf B, Schlott S, Ivanov IH. et al. Successful treatment of a refractory pyoderma gangrenosum with risankizumab. Int Wound J [Internet] 2020; 17: 1086-1088
    CrossrefPubMedSearch in Google Scholar
  • 60 Wollina U, Schönlebe J, Fürll C. Pyoderma gangrenosum induced by secukinumab – A late paradoxical drug reaction. Dermatol Ther [Internet] 2020; 33: e13161
    CrossrefPubMedSearch in Google Scholar
  • 61 Guenova E, Teske A, Fehrenbacher B. et al. Interleukin 23 Expression in Pyoderma Gangrenosum and Targeted Therapy With Ustekinumab. Arch Dermatol [Internet] 2011; 147: 1203-1205
    CrossrefPubMedSearch in Google Scholar
  • 62 Herberger K, Dissemond J, Brüggestrat S. et al. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum – analysis of 52 patients. J Dtsch Dermatol Ges 2019; 17: 32-41
    CrossrefPubMedSearch in Google Scholar
  • 63 Erfurt-Berge C, Renner R. Interdisziplinäres Vorgehen in Diagnostik und Therapie des Ulcus cruris. Aktuelle Derm [Internet] 2021; 47: 55-67
    Thieme ConnectPubMedSearch in Google Scholar